Primary Site >> Biliary tract Cancer
Gene >> KDR
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|
|
Ref: [Effects of vascular endothelial growth factor (VEGF) antisense oligodeoxynucleotide on mRNA and expression of VEGF, flt-1, and kinase insert domain containing receptor and VEGF excretion in human gallbladder carcinoma cells]. PMID: 18478945 Ref: Effective palliation of advanced cholangiocarcinoma with sorafenib: a two-patient case report. PMID: 19089671 |
Ref: Estrogens stimulate the proliferation of human cholangiocarcinoma by inducing the expression and secretion of vascular endothelial growth factor. PMID: 18395502 Ref: Endothelin inhibits cholangiocarcinoma growth by a decrease in the vascular endothelial growth factor expression. PMID: 19291182 Ref: Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma. PMID: 19319137 |
Ref: Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. PMID: 19935794 Ref: Effective treatment of advanced cholangiocarcinoma by hepatic arterial infusion chemotherapy combination with sorafenib: one case report from China. PMID: 20698202 Ref: Vascular endothelial growth factor-C promotes the growth and invasion of gallbladder cancer via an autocrine mechanism. PMID: 20734221 |
Ref: Regional differences in gallbladder cancer pathogenesis: insights from a comparison of cell cycle-regulatory, PI3K, and pro-angiogenic protein expression. PMID: 23212762 Ref: Effects of single nucleotide polymorphisms on treatment outcomes and toxicity in patients treated with sunitinib. PMID: 24123039 Ref: Down-regulation of Gab1 inhibits cell proliferation and migration in hilar cholangiocarcinoma. PMID: 24312291 |
Ref: Axitinib (AG-013736), an oral specific VEGFR TKI, shows potential therapeutic utility against cholangiocarcinoma. PMID: 24755544 Ref: Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme. PMID: 25446376 |
Ref: Phase II trial of combination therapy of gemcitabine plus anti-angiogenic vaccination of elpamotide in patients with advanced or recurrent biliary tract cancer. PMID: 25502982 Ref: Gab1 regulates proliferation and migration through the PI3K/Akt signaling pathway in intrahepatic cholangiocarcinoma. PMID: 26014518 Ref: Ischemia reperfusion of the hepatic artery induces the functional damage of large bile ducts by changes in the expression of angiogenic factors. PMID: 26451003 |
Ref: Chemotherapy for advanced biliary tract carcinoma: A meta-analysis of randomized controlled trials. PMID: 27537589 |
Ref: A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma. PMID: 28192597 Ref: Efficacy and safety of chemotherapy with or without targeted therapy in biliary tract cancer: A meta-analysis of 7 randomized controlled trials. PMID: 28397047 Ref: Axitinib for Gemcitabine-refractory Advanced Biliary Tract Cancer: Report of 5 Cases. PMID: 28668864 |
Ref: Genotyping and mRNA profiling reveal actionable molecular targets in biliary tract cancers. PMID: 29416916 Ref: Investigation of targetable predictive and prognostic markers in gallbladder carcinoma. PMID: 29564177 Ref: Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial. PMID: 29925934 Ref: Microvessel density and angiogenesis in primary hepatic malignancies: Differential expression of CD31 and VEGFR-2 in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. PMID: 29935812 Ref: HMGB1 correlates with angiogenesis and poor prognosis of perihilar cholangiocarcinoma via elevating VEGFR2 of vessel endothelium. PMID: 30177842 |